dengue%20(pediatric)
DENGUE (PEDIATRIC)
Dengue infection is caused by the dengue virus that belongs to the family Flaviviridae.
There are 4 serotypes (DENV-1, DENV-2, DENV-3, DENV-4). Each serotype provides specific lifetime protective immunity against reinfection of the same serotype, but only temporary (within 2-3 months of the primary infection) and partial protection against other serotypes.
It is transmitted to humans through the bites of infected Aedes mosquitoes. It is primarily transmitted by female Aedes aegypti, a tropical and subtropical species. Humans are the main host of the virus.
After 4-10 days of incubation period, illness begins immediately.
Drug Information

Indication: Relief of mild to moderate pain & fever.

Actimol Menstrual
pamabrom + paracetamol

Indication: Symptomatic relief of bloating, water-wt gain, backache, muscular aches, pre-menstrual & menstrual discomf...

Indication: Relief of fever & pain eg, headache, toothache, colds, flu, muscular rheumatism, dysmenorrhoea, teething p...

Indication: Relief of painful & febrile conditions eg, headache, migraine, backache, toothache, aches due to cold &...

Indication: Symptomatic relief of mild to moderate pain & fever.

Indication: Relief of mild to moderate pain including teething pain & symptomatic relief of fever in flu & feveris...

Indication: Mild to moderate pain & fever reduction.

Maxigesic
ibuprofen + paracetamol

Indication: Temporary relief of pain associated w/ headache, migraine, backache, period, dental & muscular pain, cold ...

Indication: Fever & relief of mild to moderate pain.

Indication: Analgesic & antipyretic in conditions accompanied by discomfort & fever eg, common cold & other vi...

1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 27 Jun 2019

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.